Metabolic and toxicological considerations of newly approved prostate cancer drugs

Bibliography

• Huggins C, Stephens RC, Hodges CV. Studies on prostatic cancer: 2. The effects of castration on advanced carcinoma of the prostate gland. Arch Surg 1941;43:209
   Google Scholar
• Tsao CK, Small AC, Galsky MD, et al. Overcoming castration resistance in prostate cancer. Curr Opin Urol 2012;22:167-74
   PubMed Web of Science ®Google Scholar
• Jarman M, Barrie SE, Llera JM. The 16,17-double bond is needed for irreversible inhibition of human cytochrome p45017alpha by abiraterone (17-(3-pyridyl)androsta-5, 16-dien-3beta-ol) and related steroidal inhibitors. J Med Chem 1998;41:5375-81
   PubMed Web of Science ®Google Scholar
• Li R, Evaul K, Sharma KK, et al. Abiraterone inhibits 3beta-hydroxysteroid dehydrogenase: a rationale for increasing drug exposure in castration-resistant prostate cancer. Clin Cancer Res 2012;18(13):3571-9
   PubMed Web of Science ®Google Scholar
• Attard G, Reid AH, Yap TA, et al. Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone driven. J Clin Oncol 2008;26:4563-71
   PubMed Web of Science ®Google Scholar
• Ryan CJ, Smith MR, Fong L, et al. Phase I clinical trial of the CYP17 inhibitor abiraterone acetate demonstrating clinical activity in patients with castration-resistant prostate cancer who received prior ketoconazole therapy. J Clin Oncol 2010;28:1481-8
   PubMed Web of Science ®Google Scholar
• Zytiga [package insert]. Janssen Biotech, Inc; Horsham, PA: 2012. Available from: http://www.zytigahcp.com/pdf/full_prescribing_info.pdf#zoom=100
   Google Scholar
• Acharya M, Bernard A, Gonzalez M, et al. Open-label, phase I, pharmacokinetic studies of abiraterone acetate in healthy men. Cancer Chemother Pharmacol 2012;69(6):1583-90
   PubMed Web of Science ®Google Scholar
• Attard G, Reid AH, Yap TA, et al. Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone driven. J Clin Oncol 2008;26:4563-71
   PubMed Web of Science ®Google Scholar
• Attard G, Reid AH, A'Hern R, et al. Selective inhibition of CYP17 with abiraterone acetate is highly active in the treatment of castration-resistant prostate cancer. J Clin Oncol 2009;27:3742-8
   PubMed Web of Science ®Google Scholar
• Danila DC, Morris MJ, de Bono JS, et al. Phase II multicenter study of abiraterone acetate plus prednisone therapy in patients with docetaxel-treated castration-resistant prostate cancer. J Clin Oncol 2010;28:1496-501
   PubMed Web of Science ®Google Scholar
• de Bono JS, Logothetis CJ, Molina A, et al. Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med 2011;364:1995-2005
   PubMed Web of Science ®Google Scholar
• Sternberg CN, Molina A, North S, et al. Effect of abiraterone acetate on fatigue in patients with metastatic castration-resistant prostate cancer after docetaxel chemotherapy. Ann Oncol 2013;24(4):1017-25
   PubMed Web of Science ®Google Scholar
• Logothetis CJ, Basch E, Molina A, et al. Effect of abiraterone acetate and prednisone compared with placebo and prednisone on pain control and skeletal-related events in patients with metastatic castration-resistant prostate cancer: exploratory analysis of data from the COU-AA-301 randomised trial. Lancet Oncol 2012;13(12):1210-17
   PubMed Web of Science ®Google Scholar
• Ryan CJ, Smith MR, De Bono JS, et al. Interim analysis (IA) results of COU-AA-302, a randomized, phase III study of abiraterone acetate (AA) in chemotherapy-naive patients (pts) with metastatic castration-resistant prostate cancer (mCRPC). J Clin Oncol 2012;30:abstract LBA4518
   Google Scholar
• Taplin ME, Montgomery RB, Logothetis C, et al. Effect of neoadjuvant abiraterone acetate (AA) plus leuprolide acetate (LHRHa) on PSA, pathological complete response (pCR), and near pCR in localized high-risk prostate cancer (LHRPC): Results of a randomized phase II study [abstract 4521]. 2012 ASCO Annual Meeting
   Google Scholar
• Mezynski J, Pezaro C, Bianchini D, et al. Antitumour activity of docetaxel following treatment with the CYP17A1 inhibitor abiraterone: clinical evidence for cross-resistance? Ann Oncol 2012;23(11):2943-7
   PubMed Web of Science ®Google Scholar
• Tran C, Ouk S, Clegg NJ, et al. Development of a second-generation antiandrogen for treatment of advanced prostate cancer. Science 2009;324:787-90
   PubMed Web of Science ®Google Scholar
• Kolvenbag GJ, Furr BJ, Blackledge GR. Receptor affinity and potency of non-steroidal antiandrogens: translation of preclinical findings into clinical activity. Prostate Cancer Prostatic Dis 1998;1:307-14
   PubMed Web of Science ®Google Scholar
• Scher HI, Beer TM, Higano CS, et al. Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1-2 study. Lancet 2010;375:1437-46
   PubMed Web of Science ®Google Scholar
• Xtandi [package insert]. Astellas Pharma US, Inc; Northbrook, IL: 2012. Available from: http://www.astellas.us/docs/us/12A005-ENZ-WPI.pdf
   Google Scholar
• Scher HI, Fizazi K, Saad F, et al. Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med 2012;367:1187-97
   PubMed Web of Science ®Google Scholar
• Jordan MA, Wilson L. Microtubules as a target for anticancer drugs. Nat Rev Cancer 2004;4:253-65
   PubMed Web of Science ®Google Scholar
• Available from: http://clinicaltrials.gov/ct2/show/NCT01212991?term=prevail&rank=6 [Access on 9th December 2012]
   Google Scholar
• Mitsiades N, Sung CC, Schultz N, et al. Distinct patterns of dysregulated expression of enzymes involved in androgen synthesis and metabolism in metastatic prostate cancer tumors. Cancer Res 2012;72(23):6142-52
   PubMed Web of Science ®Google Scholar
• Mita AC, Denis LJ, Rowinsky EK, et al. Phase I and pharmacokinetic study of XRP6258 (RPR 116258A), a novel taxane, administered as a 1-hour infusion every 3 weeks in patients with advanced solid tumors. Clin Cancer Res 2009;15:723-30
   PubMed Web of Science ®Google Scholar
• Mita AC, Denis LJ, Rowinsky EK, et al. Phase I and pharmacokinetic study of XRP6258 (RPR 116258A), a novel taxane, administered as a 1-hour infusion every 3 weeks in patients with advanced solid tumors. Clin Cancer Res 2009;15:723-30
   PubMed Web of Science ®Google Scholar
• JEVTANA® (Cabazitaxel): package insert. Sanofi-Aventis US, LLC; Cambridge, MA: 2012. Available from: http://products.sanofi.us/jevtana/jevtana.pdf
   Google Scholar
• De Bono JS, Oudard S, Ozguroglu M, et al. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet 2010;376:1147-54
   PubMed Web of Science ®Google Scholar
• Villanueva C, Awada A, Campone M, et al. A multicentre dose-escalating study of cabazitaxel (XRP6258) in combination with capecitabine in patients with metastatic breast cancer progressing after anthracycline and taxane treatment: a phase I/II study. Eur J Cancer 2011;47(7):1037-45
   PubMed Web of Science ®Google Scholar
• Available from: http://clinicaltrials.gov/ct2/show/NCT01308580?term=cabazitaxel+20mg&rank=2 [Accessed on 9 December 2012]
   Google Scholar
• Steinman RM, Cohn ZA. Identification of a novel cell type in peripherallymphoid organs of mice. I. Morphology, quantitation, tissue distribution. J Exp Med 1973;137:1142-62
   PubMed Web of Science ®Google Scholar
• Hammerstrom AE, Cauley DH, Atkinson BJ, et al. Cancer immunotherapy: sipuleucel-T and beyond. Pharmacotherapy 2011;31(8):813-28
   PubMed Web of Science ®Google Scholar
• Provenge® (Sipuleucel-T): package insert. Dendreon Corportation; Seattle, Washington: 2011. Available from: http://www.provenge.com/pdf/prescribing-information.pdf
   Google Scholar
• Sonpavde G, Di Lorenzo G, Higano CS, et al. The role of sipuleucel-t in therapy for castration-resistant prostate cancer: a critical analysis of the literature. Eur Urol 2012;61(4):639-47
   PubMed Web of Science ®Google Scholar
• Higano CS, Schellhammer PF, Small EJ, et al. Integrated data from 2 randomized, double-blind, placebo-controlled, phase 3 trials of active cellular immunotherapy with sipuleucel-T in advanced prostate cancer. Cancer 2009;115:3670-9
   PubMed Web of Science ®Google Scholar
• Kantoff PW, Higano CS, Shore ND, et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med 2010;363:411-22
   PubMed Web of Science ®Google Scholar
• Kawalec P, Paszulewicz A, Holko P, et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. A systematic review and meta-analysis. Arch Med Sci 2012;8(5):767-75
   PubMed Web of Science ®Google Scholar
• Joniau S, Abrahamsson PA, Bellmunt J, et al. Current vaccination strategies for prostate cancer. Eur Urol 2012;61(2):290-306
   PubMed Web of Science ®Google Scholar
• Parker C, Heinrich D, O'Sullivan JM, et al. on behalf of the ALSYMPCA Investigators. Overall survival benefitof radium-223 chloride (Alpharadin) in the treatment of patients with symptomatic bone metastases in castration-resistant prostate cancer (CRPC): a phase III randomised trial (ALSYMPCA). ASCO Annual Meeting Proceedings (Post-Meeting Edition). J Clin Oncol 2012. 30(18 Suppl): LBA4512; June 20 Supplement
   Google Scholar
• Pisters LL, Troncoso P, Zhau HE, et al. c-met proto-oncogene expression in benign and malignant human prostate tissues. J Urol 1995;154:293-8
   PubMed Web of Science ®Google Scholar
• Knudsen BS, Gmyrek GA, Inra J, et al. High expression of the met receptor in prostate cancer metastasis to bone. Urology 2002;60:1113-17
   PubMed Web of Science ®Google Scholar
• Verras M, Lee J, Xue H, et al. The androgen receptor negatively regulates the expression of c-Met: implications for a novel mechanism of prostate cancer progression. Cancer Res 2007;67:967-75
   PubMed Web of Science ®Google Scholar
• Kurzrock R, Sherman SI, Ball DW, et al. Activity of XL184 (cabozantinib), an oral tyrosine kinase inhibitor, in patients with medullary thyroid cancer. J Clin Oncol 2011;29:2660-6
   PubMed Web of Science ®Google Scholar
• Smith DC, Smith MR, Sweeney C, et al. Cabozantinib in patients with advanced prostate cancer: results of a phase II randomized discontinuation trial. J Clin Oncol 2013;31(4):412-19
   PubMed Web of Science ®Google Scholar